SS-31 (Elamipretide) (10mg)
Spécifications techniques
| Pureté (HPLC) | ≥98% (HPLC) |
| Numéro CAS | 736992-21-5 |
| Forme | White lyophilized powder |
| Stockage | -20°C |
| Séquence | D-Arg-Dmt-Lys-Phe-NH₂ |
| Poids moléculaire | 640.81 g/mol |
| Forme saline | Acetate |
| Solubilité | Soluble in water |
SS-31 (Elamipretide) (10mg)
Prix catalogue EUR · HU, SK, CZ, PL
- Eurozone (EUR)105,30 EUR
- Hongrie (HU)105,30 EUR≈ 42 120 Ft
- Slovaquie (SK)105,30 EUR
- Tchéquie (CZ)105,30 EUR≈ 2 633 Kč
- Pologne (PL)105,30 EUR≈ 447,53 zł
Même prix catalogue en EUR pour livraison vers la Hongrie, la Slovaquie, la République tchèque et la Pologne. Paiement en EUR.
Montants HUF/CZK/PLN indicatifs convertis depuis l’EUR ; la Slovaquie utilise l’EUR. Taux approximatifs. Paiement en EUR.
Mitochondria-targeted tetrapeptide for cellular energy research.
Mechanism: Stabilizes cardiolipin, optimizes electron transport, reduces ROS.
Applications: Heart failure, ischemia-reperfusion, mitochondrial myopathies.
Note: Concentrates 1000-5000x in mitochondria.
Strictement réservé à la recherche en laboratoire.
Non destiné à la consommation humaine, vétérinaire ou au diagnostic.
From the Peptide Explorer
A mitochondria-targeted tetrapeptide that concentrates >1000-fold in the inner mitochondrial membrane, selectively binding cardiolipin. By stabilizing cardiolipin-cytochrome c interactions, SS-31 optimizes electron transport chain efficiency and reduces ROS production at the source.
Key Mechanisms
- ›Cardiolipin binding in inner mitochondrial membrane
- ›Electron transport chain optimization
- ›ROS reduction at source (not scavenging)
- ›Cytochrome c stabilization
- ›Mitochondrial membrane potential preservation
Primary Research Areas
- ›Mitochondrial dysfunction
- ›Heart failure
- ›Renal ischemia
- ›Barth syndrome
- ›Age-related mitochondrial decline
Key Research Findings
- Concentrated >1000-fold in mitochondria within minutes
- Improved cardiac function in heart failure models (Dai et al., JACC, 2013)
- Advanced to Phase 3 clinical trials for Barth syndrome
Research Overview
A mitochondria-targeted tetrapeptide that concentrates >1000-fold in the inner mitochondrial membrane, selectively binding cardiolipin. By stabilizing cardiolipin-cytochrome c interactions, SS-31 optimizes electron transport chain efficiency and reduces ROS production at the source.
Origin: Developed by Dr. Hazel Szeto at Weill Cornell Medicine
Mechanism of Action
- Cardiolipin binding in inner mitochondrial membrane
- Electron transport chain optimization
- ROS reduction at source (not scavenging)
- Cytochrome c stabilization
- Mitochondrial membrane potential preservation
Primary Research Areas
- Mitochondrial dysfunction
- Heart failure
- Renal ischemia
- Barth syndrome
- Age-related mitochondrial decline
Key Published Findings
- Concentrated >1000-fold in mitochondria within minutes
- Improved cardiac function in heart failure models (Dai et al., JACC, 2013)
- Advanced to Phase 3 clinical trials for Barth syndrome
Research Protocol
Commonly studied routes: Subcutaneous, Intravenous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized
Important Notice
SS-31 (Elamipretide) (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Spécifications de recherche
Synthesized for strict analytical consistency. Verified via HPLC/MS.Voir les standards qualité →
Manipulation et stockage
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water